Dr. Reynolds is deputy director of the Division of Clinical Pharmacology IV in the Office of Clinical Pharmacology, Center for Drug Evaluation and Research, FDA. Dr. Reynolds received her B.S. in Biochemistry from Virginia Tech, her Pharm.D. from Virginia Commonwealth University, and completed a fellowship in Clinical Pharmacokinetics and Drug Development at the University of North Carolina at Chapel Hill. Her work involves application of clinical pharmacology to the development of antiviral, anti-infective, transplant, and ophthalmology drugs. Dr. Reynolds’ interests include dose selection for patient sub-populations; factors affecting drug absorption, drug metabolism, drug interactions; and communication of drug use information to health care providers and patients. At FDA she is a member of the Renal Impairment Working Group, Antibiotic Drug Development Task Force, and Drug Interaction Working Group.
Dr. Reynolds has given presentations on interpretation of in vitro and in vivo drug interaction data and the design of in vivo drug interaction studies. She has published peer-reviewed articles and book chapters that address drug interactions.
Dr. Reynolds is currently president of the American Society for Clinical Pharmacology and Therapeutics and served in other leadership roles. She was previously an associate editor for the journal Clinical Pharmacology and Therapeutics.